To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

NCT05483907 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

129

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: BBT-877
DRUG: Placebo

Sponsor

Bridge Biotherapeutics, Inc.